Lifecore Biomedical Posts Strong Revenue Growth, Eyes Mid-Term Margin Expansion
Event summary
- Lifecore Biomedical reported $35.7 million in Q4 2025 revenues, up 10% YoY, and $75.5 million for the seven-month transition period ending December 31, 2025, a 20% increase YoY.
- Gross profit margin improved to 31% from 26% YoY, with operating expenses down 31% YoY to $24.4 million.
- Signed five new programs in 2025, including three in Q4, and launched a new ERP system in January 2026 to enhance operational efficiency.
- Guidance for 2026 projects revenues of $120–125 million, with Adjusted EBITDA ranging from $20.5–25 million.
The big picture
Lifecore Biomedical's strong financial performance in 2025 reflects its strategic focus on operational efficiency and pipeline expansion. The company's ability to improve margins while signing new programs positions it for sustained growth, though it must navigate customer concentration risks and debt obligations to meet its mid-term targets. The biotech CDMO sector continues to emphasize cost discipline and capacity utilization as key drivers of long-term success.
What we're watching
- Revenue Diversification
- Whether Lifecore can sustain growth by broadening its customer base beyond its largest client, particularly as it targets a 12% revenue CAGR through 2029.
- Margin Expansion
- The pace at which Lifecore achieves its goal of EBITDA margins above 25% amid ongoing cost containment and efficiency initiatives.
- Debt Management
- How Lifecore navigates potential redemptions of Series A Convertible Preferred Stock beginning June 29, 2026, with an aggregate liquidation preference of $50.2 million.
Related topics